Experienced in Herniated Disk

Ron Milo

Rehovot, M, IL 
Experienced in Herniated Disk
Rehovot, M, IL 
OverviewLocationsClinical Research

Overview

Ron Milo practices in Rehovot, Israel. Mr. Milo is rated as an Experienced expert by MediFind in the treatment of Herniated Disk. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Creutzfeldt-Jakob Disease, and Relapsing Multiple Sclerosis (RMS).

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Herniated Disk.

Gender
Male

Locations

Rehovot, M, Israel
Other Locations
Ashkelon, D, Israel
Beersheba, D, Israel
Tel Aviv, TA, Israel
Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drug: GA Depot 
Study Phase: Phase 2
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

147 Total Publications

Reply to Apanovich and Weeks: Exceptions exist, as recognized in the paper, but are too rare to challenge the original findings.
Reply to Apanovich and Weeks: Exceptions exist, as recognized in the paper, but are too rare to challenge the original findings.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Milo's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile